Patents Assigned to Istituto di Ricerche di Biologia Molecolare P. Angeletti, S.R.L.
  • Publication number: 20140094405
    Abstract: The present invention relates to compounds comprising at least ten contiguous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 3, 2014
    Applicant: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.r.l.
    Inventors: Antonello PESSI, Elisabetta Bianchi, Paolo Ingallinella
  • Patent number: 8629101
    Abstract: The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: January 14, 2014
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.r.l.
    Inventors: Antonello Pessi, Elisabetta Bianchi, Paolo Ingallinella
  • Patent number: 8377873
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: February 19, 2013
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca, Maria Emilia Di Francesco, Marco Pompei
  • Patent number: 8362030
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: January 29, 2013
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.
    Inventors: Raffaele Ingenito, Philip Jones, Laura Llauger Bufi, Jesus Maria Ontoria Ontoria, Rita Scarpelli
  • Patent number: 8354413
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: January 15, 2013
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti, S.R.L.
    Inventors: Philip Jones, Olaf Kinzel, Uwe Koch, Jesus Maria Ontoria Ontoria, Giovanna Pescatore, Rita Scarpelli, Caterina Torrisi